Respira Technologies, Inc. launches pharmaceutical focused commercial development platform to pursue API delivery partnerships with its proprietary RespiRx™ medical device platform

- RespiRx™ is an innovative, vibrating mesh, API agnostic delivery device with broad application for the delivery of thermo and pressure sensitive drug complexes across multiple target markets

News provided by

Respira Technologies, Inc.

Jun 02, 2020, 08:00 ET

WEST HOLLYWOOD, Calif., June 2, 2020 /PRNewswire/ -- Respira Technologies, Inc., a health-technology platform development company, announced today the launch of its pharmaceutical focused commercial development program for the RespiRx^TM drug delivery device platform.

Respira Technologies' mission is to improve the standard of patient care and to improve public health outcomes by creating and commercializing cutting-edge drug delivery platforms. Founder and CEO, Mario Danek stated, "The current landscape of drug delivery platforms lacks the patient focused attributes necessary to address the high rate of patient misuse of daily controller medications, including nebulizers."

Danek created the ResipRx^TM to be the first truly patient focused & ultra-portable handheld Vibrating Mesh Nebulizer (VMN) for local and systemic treatment. The RespiRx^TM combines breakthrough performance and superior human factors for vastly improved patient care & outcomes, across the fullest spectrum of pressure and thermo sensitive APIs.

Danek stated, "The RespiRx^TM was created to address the patient's unmet needs for improved care. The current landscape of medical aerosolizing devices being offered for treatment today, require ongoing cleaning and maintenance by the user and often are lacking in features such as Bluetooth-enabled mobile applications for real time accurate dose measurement - all of which the RespiRx^TM provides."

The RespiRx^TMis the first orientation agnostic VMN device that effectively operates portably and in any position held by the patient. Current generation nebulizers are gravity fed, which limits usage occasions and can lead to improper use and/or lower rates of drug delivery efficacy as the device must be held in an upright position for proper operation, sometimes straining the inspiratory abilities of patients struggling with respiratory function. Multiple studies have shown high rates of nebulizer misuse due to their design limitations and thus, are a likely cofactor as to why adherence rates for daily controller medications are under 40%.

In addition, the RespiRx^TM has a pre-filled cartridge or TSDC^TM(Total System Delivery Cartridge) that includes a disposable piezo element and the drug compound suspended in an aqueous solution. This unique format improves convenience and eliminates the opportunity for patient error and misuse due to lack of proper cleaning. The TSDC^TM is programmable for precise dose delivery and is Bluetooth enabled for dose delivery tracking, measurement, and EMR data collection for the health care provider.

The company sees significant opportunity to combine its drug delivery technologies in partnership with drug development companies. Target indications for the RespiRx^TM include the treatment of asthma, COPD, potential vaccine delivery, pain management, nicotine replacement therapy, and investigative new drugs such as inhalable insulin.

About Respira Technologies, Inc.

Respira is based in West Hollywood, CA and was founded by CEO, Mario Danek in 2018, to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies.

Respira has developed two proprietary platforms, an API agnostic drug delivery platform for water-soluble, thermosensitive drug compounds and a LOW-HEAT device platform for water-insoluble compounds. Both device platforms are portable, orientation agnostic, and require no cleaning.

The company is backed by venture firms: DG incubation, Evolution VC Partners and Poseidon Asset Management.

www.respiratechnologies.com

[email protected]

SOURCE Respira Technologies, Inc.